"Mrs Lusia Guthrie (recently retired LBT CEO and Chairman of CCS), confirmed that CCS is in continuing discussions with significant global diagnostics companies for the licensing of the APAS product portfolio, including APAS Independence and APAS Incubot, plus flow-on product opportunities on the drawing board all aimed at the clinical microbiology laboratory."
In other words a party or parties are going to get beaten out here by their opposition. LBT are most likely in a very powerful position.
"Mrs Lusia Guthrie (recently retired LBT CEO and Chairman of...
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $22.88M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.5¢ | 1.4¢ | $10.59K | 740.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1249925 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 559699 | 2 |
View Market Depth
| Last trade - 12.19pm 05/09/2024 (20 minute delay) ? |
| LBT (ASX) Chart |